AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06683807
Drug: Hyperbaric bupivacaine 0.5% (2.5 mL) aspirated 5 minutes delayed after opening the bupivacaine ampule
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parturients will receive spinal anesthesia for elective cesarean delivery with injection of 25 μg fentanyl plus 12.5 mg of hyperbaric bupivacaine 0.5% (2.5 mL) directly after 5 min' delayed aspiration from opening of the bupivacaine ampule with an unfiltered 3 ml syringe to allow glass particles to settle onto the bottom of the ampule
Trial: NCT05772156
Drug: Methylergonovine
RxNorm normalized name: methylergonovine
DrugBank: Methylergometrine (DB00353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylergonovine 200mcg Intramuscular (IM)
Trial: NCT05892393
Drug: Zirconium Zr 89-DFO-YS5
RxNorm normalized name: zirconium
DrugBank: Aluminum zirconium trichlorohydrex gly (DB11116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06534723
Drug: Wujia Yizhi granules
RxNorm normalized name: Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (propiolactone inactivated)
DrugBank: Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (propiolactone inactivated) (DB10780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Wujia Yizhi granuless
Trial: NCT05515575
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each patient will receive niraparib daily in 21-day cycles until disease progression or unacceptable toxicity. Mandatory baseline tumor biopsies will occur during study screening, if feasible.
Trial: NCT04741074
Drug: Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose will be started at 0.25 mg per week. Dose escalation will occur every 4 weeks to mitigate risk of gastrointestinal side effects to a maximum dose of 1.0 mg per week.
Trial: NCT06610747
Drug: Aflibercept 2Mg/0.05Ml Inj,Oph
RxNorm normalized name: AFLIBERCEPT 2MG/0.05ML INJ,OPH
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each eye will receive three to five q4week loading anti-VEGF injections of aflibercept (2-mg, EYLEA®) after enrollment to complete the initial loading phase of 5 doses. Each eye will then be treated according to the PRN treatment protocol described in the study protocol.
Trial: NCT06096220
Drug: Application of Carnoy solution
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carnoy solution will be applied during the enucleation as described previously
Trial: NCT05747729
Drug: Surufatinib and Serplulimab
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib: Safety lead-in : Oral, QD, starting dose 250 mg, adjusted according to DLT. Dose expansion: administration according to the dose determined in the safety lead-in phase.~Serplulimab: 300 mg intravenous infusion on day 1, repeated every 3 weeks.
Trial: NCT06090799
Drug: SHR-3032
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose at varying dosage levels depending on treatment assignment
Trial: NCT06105255
Drug: D-1553
RxNorm normalized name: D
DrugBank: Rosomidnar (DB17154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-1553 is a novel, targeted KRASG12C inhibitor.
Trial: NCT04874194
Drug: Omacetaxine Mepesuccinate
RxNorm normalized name: Omacetaxine Mepesuccinate
DrugBank: Omacetaxine mepesuccinate (DB04865)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT04874194
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05284617
Drug: HU6
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HU6 is being evaluated for its efficacy in improving cardiovascular function in obese subjects with HF with preserved ejection fraction (HFpEF).
Trial: NCT05811949
Drug: Dimethyl Fumarate 240 MG [Tecfidera]
RxNorm normalized name: dimethyl fumarate 240 MG [Tecfidera]
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DMF is admnistered to RRMS patients who are candidates for treatment according to clinical practice at a dosage of 120 mg twice daily, increased to 240 mg twice daily after 7 days.
Trial: NCT04909333
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive Exenatide study medication according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of Exenatide, a 10ml 0.9% saline solution will be administered intravenously.
Trial: NCT05003076
Drug: Methamphetamine
RxNorm normalized name: Methamphetamine
DrugBank: Metamfetamine (DB01577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be given 20 mg of Methamphetamine.
Trial: NCT04612556
Drug: Mepolizumab 100 MG [Nucala]
RxNorm normalized name: mepolizumab 100 MG [Nucala]
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subcutaneous injection once a month
Trial: NCT02832531
Drug: Rivaroxaban (15 mg)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~1. Left atrial enlargement ≥ 5.5 cm, OR~2. Left atrial spontaneous echo contrast OR~3. Left atrial thrombus OR~4. Frequent ectopic atrial activity (\>1000/24 hours) on Holter ECG.
Trial: NCT02832531
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~1. Left atrial enlargement ≥ 5.5 cm, OR~2. Left atrial spontaneous echo contrast OR~3. Left atrial thrombus OR~4. Frequent ectopic atrial activity (\>1000/24 hours) on Holter ECG.
Trial: NCT06290713
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given either the intervention medication or a placebo (double-blinded, randomized trial) and will be asked to take the medication every day for 6 months in conjunction with weekly exercise sessions.
Trial: NCT00002171
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06261320
Drug: Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 sessions of mesotherapy (mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate), with intra-epidermal and intra-hypodermal technics.
Trial: NCT06024421
Drug: favipiravir
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Light yellow, film-coated tablet, each containing 200 mg of favipiravir
Trial: NCT03970031
Drug: MSDC-0602K
RxNorm normalized name: MSDC-0160
DrugBank: Mitoglitazone (DB11721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSDC-0602K tablet
Trial: NCT06637189
Drug: Ganirelix
RxNorm normalized name: Ganirelix
DrugBank: Ganirelix (DB06785)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitively binding to GnRH receptors in the pituitary gland. Consequently, there is a reversible, intense, and rapid suppression of endogenous gonadotropin release. Ganirelix is indicated for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive techniques (ART).
Trial: NCT06637189
Drug: Medroxyprogesterone Acetate 10 MG
RxNorm normalized name: medroxyprogesterone acetate 10 MG
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate is a synthetic progestin (structurally related to progesterone) with antiestrogenic, antiandrogenic, and antigonadotropic action. It inhibits pituitary gonadotropins (FSH and LH) with consequent inhibition of follicular maturation and ovulation . Medroxyprogesterone acetate is active orally and parenterally, 15 times more potent than progesterone. In addition to inhibiting ovulation, progestins also act on the endometrium preventing implantation and increasing the viscosity of cervical mucus, which hinders sperm progression in the uterus. It also transforms a proliferative endometrium into a secretory endometrium, provided that the woman has adequate endogenous estrogen levels.
Trial: NCT06640621
Drug: Different concentration of ropivacaine for single brachial plexus block
RxNorm normalized name: Ivy Block
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 ASA grade I - II patients were selected from the patients who underwent shoulder ligament rupture repair surgery under selective general anesthesia combined with brachial plexus block analgesia in the sports medical center of our hospital. They were randomly divided into two groups: high concentration group (group I) and low concentration group (Group II), with 20 cases in each group. 40 patients underwent a single brachial plexus block under ultrasound guidance before general anesthesia.
Trial: NCT05954624
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT05954624
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT05954624
Drug: Probenecid
RxNorm normalized name: Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03202147
Drug: Cromolyn
RxNorm normalized name: Cromolyn
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active capsules for inhalation.
Trial: NCT05384483
Drug: Cariprazine
RxNorm normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cariprazine 1.5 to 3 mg per day
Trial: NCT06582732
Drug: Travoprost Intracameral Implant exchanged at Month 12
RxNorm normalized name: travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 12
Trial: NCT06582732
Drug: Travoprost Intracameral Implant exchanged at Month 3
RxNorm normalized name: travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 3
Trial: NCT06582732
Drug: Travoprost Intracameral Implant exchanged at Month 6
RxNorm normalized name: travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 6
Trial: NCT06582732
Drug: Travoprost Intracameral Implant exchanged at Month 24
RxNorm normalized name: travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 24
Trial: NCT06582732
Drug: Travoprost intracameral implant exchanged at Month 21
RxNorm normalized name: travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 21
Trial: NCT06582732
Drug: Travoprost intracameral implant exchanged at Month 18
RxNorm normalized name: travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 18
Trial: NCT06582732
Drug: Travoprost intracameral implant exchanged at Month 15
RxNorm normalized name: travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 15
Trial: NCT06644794
Drug: Progesterone-modified natural cycle preparation for frozen embryo transfer
RxNorm normalized name: human embryo tissue preparation
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A novel endometrial preparation protocol that optimizes the natural cycle, whereby as long as the thickness of the endometrium is suitable for embryo transfer, vaginal progesterone can be used to transform the endometrium before ovulation and subsequently FET.
Trial: NCT06351020
Drug: LM-302
RxNorm normalized name: LM-030
DrugBank: LM-030 (DB18283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LM-302 intravenous-injection every 2 weeks on Day 1 of each 14-day cycle
Trial: NCT06351020
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive Apatinib orally,qd
Trial: NCT06351020
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subjects will receive Irinotecan intravenous-injection,every 2 weeks on Day 1 of each 14-day cycle
Trial: NCT05541016
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05484557
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: treatment for 6 to 12 weeks
Trial: NCT05484557
Drug: Enoxaparin Sodium
RxNorm normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment for 6 to 12 weeks
Trial: NCT05301192
Drug: Angiotensin-(1-7)
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
Trial: NCT05301192
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline will be used as the placebo comparator.
Trial: NCT05541016
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05823441
Drug: Oxytocin nasal spray
RxNorm normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Volunteers inhale 24 units of oxytocin spray
Trial: NCT06386848
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
DrugBank: Botulinum toxin type B (DB00042)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin doses injected in dystonia
Trial: NCT00002130
Drug: Vesnarinone
RxNorm normalized name: VESNARINONE
DrugBank: Vesnarinone (DB12082)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05375929
Drug: Abrocitinib 100 mg
RxNorm normalized name: abrocitinib 100 MG
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally administered, abrocitinib 100 mg tablets QD
Trial: NCT05375929
Drug: Abrocitinib 200 mg
RxNorm normalized name: abrocitinib 200 MG
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally administered, abrocitinib 200 mg tablets QD.
Trial: NCT06381791
Drug: Epidiolex
RxNorm normalized name: Epidiolex
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150mg of Epidiolex
Trial: NCT06381960
Drug: Fuzheng Quxie Recipe
RxNorm normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group: Fuzheng Quxie Recipe (Yifei Sanjie Recipe) ingredients: Sheng Huang Qi 15g, Jiao Bai Zhu 15g, Bai Fu Ling 15g, Bei Sha Shen 15g, Zhe Mai Dong 15g, Dang Shen 15g, Shu Yang Quan 15g, Xia Ku Cao 15g, Sheng Mu Li 15g, Shi Jian Chuan 15g, Shi Shang Bai 15g, and Hai Zao 15g. Combined with basic chemotherapy after lung cancer.
Trial: NCT04939909
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Patients were treated with Botulinum toxin type A applications on the Orbicularis oculi and glabellar complex
Trial: NCT05822245
Drug: PER-001 Intravitreal Implant - Low Dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PER-001 Low Dose Intravitreal Implant
Trial: NCT05822245
Drug: PER-001 Intravitreal Implant - High Dose
RxNorm normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PER-001 High Dose Intravitreal Implant
Trial: NCT05822245
Drug: PER-001 Intravitreal Implant - Sham
RxNorm normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PER-001 Intravitreal Sham
Trial: NCT04650893
Drug: Intravenous Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
Trial: NCT05919030
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg IV Q3W
Trial: NCT05919030
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During concurrent radiation therapy: 25 mg/m² IV QW During consolidation therapy: 75 mg/m² IV Q3W
Trial: NCT05919030
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: During concurrent radiation therapy: 75 mg/m² IV QW During consolidation therapy: 220 mg/m² IV Q3W
Trial: NCT05487391
Drug: QL1706 injection
RxNorm normalized name: QL1706
DrugBank: QL1706 (DB17562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL1706(5mg/kg Q3W IV) concomitantly with Platinum-based chemotherapy
Trial: NCT05487391
Drug: Vinorelbine Tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25mg/m2（D1、D8）Q3W IV, 2-4 cycles
Trial: NCT05487391
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175mg/m2（D1） Q3W IV, 2-4 cycles
Trial: NCT05487391
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75mg/m2（D1）Q3W IV, 2-4 cycles
Trial: NCT05487391
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC=5（D1） Q3W IV, 2-4 cycles
Trial: NCT05487391
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed 500mg/m2（D1） Q3W IV, 2-4 cycles
Trial: NCT05670184
Drug: LSD
RxNorm normalized name: LSD
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of LSD (50 µg) will be administered in a small amount of alcohol (ethanol, 2ml/95% Vol.) orally.
Trial: NCT05617885
Drug: Darolutamide
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet administered orally, per protocol, 2 x daily. Darolutamide is an orally administered molecular drug therapy that blocks the action of testosterone, the male sex hormone which can stimulate growth of prostate cancer.
Trial: NCT05617885
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet administered orally, per protocol, 2 x daily. Abemaciclib is an orally administered molecular drug therapy that is called a CDK4/6 inhibitor. CDK4 and CDK6 are enzymes that are involved in helping healthy and cancerous cells divide and blocking these enzymes can stop cancerous cells from growing.
Trial: NCT05617885
Drug: GNRH-A Leuprolide Acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via intramuscular injection, per standard of care. GnRH agonist is a hormonal therapy drug.
Trial: NCT05617885
Drug: GNRH-A Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered via subcutaneous injection, per standard of care. GnRH agonist is a hormonal therapy drug.
Trial: NCT05617885
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered via subcutaneous injection, per standard of care. GnRH antagonist is a hormonal therapy drug.
Trial: NCT05183984
Drug: Bevacizumab-Awwb
RxNorm normalized name: bevacizumab-awwb
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: MVASI (bevacizumab biosimilar) will be administrated by intravenous infusion at the second chemotherapy cycle for 5 cycles.~the administration will continue during maintenance phase. Total bevacizumab duration therapy is 15 months.
Trial: NCT05183984
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: niraparib will be administered orally once daily continuously after chemotherapy (+/- bevacizumab) cycles (maintenance treatment period). Total niraparib duration mainance treatment period is 2 years.